CY1114116T1 - Συζευγματα για στοχευμενη απελευθερωση φαρμακων κατα μηκος του αιματοεγκεφαλικου φραγμου - Google Patents

Συζευγματα για στοχευμενη απελευθερωση φαρμακων κατα μηκος του αιματοεγκεφαλικου φραγμου

Info

Publication number
CY1114116T1
CY1114116T1 CY20131100577T CY131100577T CY1114116T1 CY 1114116 T1 CY1114116 T1 CY 1114116T1 CY 20131100577 T CY20131100577 T CY 20131100577T CY 131100577 T CY131100577 T CY 131100577T CY 1114116 T1 CY1114116 T1 CY 1114116T1
Authority
CY
Cyprus
Prior art keywords
blood
targeted
drugs
liberty
consumptions
Prior art date
Application number
CY20131100577T
Other languages
English (en)
Inventor
Pieter Jaap Gaillard
Original Assignee
To-Bbb Holding B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by To-Bbb Holding B.V. filed Critical To-Bbb Holding B.V.
Publication of CY1114116T1 publication Critical patent/CY1114116T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση σχετίζεται με μεθόδους στοχευμένης απελευθέρωσης φαρμάκων αντι-ιικών ενώσεων, που συμπεριλαμβάνουν, χημικούς παράγοντες (όπως τα ανάλογα νουκλεοζιδίων ή οι αναστολείς πρωτεάσης) και φάρμακα βάσει πυρηνικών οξέων(όπως τα εμβόλια DΝΑ, τα ολιγονουκλεοτίδια αντίθετης φοράς, τα ριβοσωμάτια, τα καταλυτικά μόρια DΝΑ (DΝΑζυμα) ή RΝΑ, τα siRΝΑs ή τα πλασμίδια που εγκωδικεύονται εκ τούτων). Προσέτι, η εφεύρεση σχετίζεται με στοχευμένη απελευθέρωση φαρμάκων αντι-ιικών ενώσεων σε σημεία ενδοκυτταρικών στόχων στα πλαίσια των κυττάρων, ιστών και οργάνων, ειδικότερα δε σε σημεία στόχων στα πλαίσια του κεντρικού νευρικού συστήματος (ΚΝΣ), μέσα στον και κατά μήκος του αιματο-εγκεφαλικού φραγμού, στοχεύοντας υποδοχείς πρόσληψης εσωτερικοποίησης που εμφανίζονται επ' αυτών των κυττάρων, ιστών και οργάνων. Εις τούτο, οι αντι-ιικές ενώσεις, ή η φαρμακευτικώς αποδεκτή ουσία-φορέας εξ αυτών, συζεύγνυνται σε προσδέτες που διευκολύνουν την ειδική δέσμευση στους και την εσωτερικοποίηση από αυτούς τους υποδοχείς.
CY20131100577T 2007-03-23 2013-07-08 Συζευγματα για στοχευμενη απελευθερωση φαρμακων κατα μηκος του αιματοεγκεφαλικου φραγμου CY1114116T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90717607P 2007-03-23 2007-03-23
EP11152915.2A EP2308514B1 (en) 2007-03-23 2008-03-21 Conjugates for targeted drug delivery across the blood-brain barrier

Publications (1)

Publication Number Publication Date
CY1114116T1 true CY1114116T1 (el) 2016-07-27

Family

ID=39485128

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100577T CY1114116T1 (el) 2007-03-23 2013-07-08 Συζευγματα για στοχευμενη απελευθερωση φαρμακων κατα μηκος του αιματοεγκεφαλικου φραγμου

Country Status (11)

Country Link
US (4) US20100129437A1 (el)
EP (2) EP2308514B1 (el)
CY (1) CY1114116T1 (el)
DK (1) DK2308514T3 (el)
ES (1) ES2426684T3 (el)
HR (1) HRP20130547T1 (el)
PL (1) PL2308514T3 (el)
PT (1) PT2308514E (el)
SI (1) SI2308514T1 (el)
TW (2) TWI537005B (el)
WO (1) WO2008118013A2 (el)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249838T3 (es) * 1997-07-11 2006-04-01 The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services Inmunogenos quimericos similares a la exotoxina a de pseudomonas.
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
JP2008512445A (ja) * 2004-09-09 2008-04-24 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 炎症状態の治療のためのリポソーム性グルココルチコイドの使用
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008147526A1 (en) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
AU2009206673B2 (en) 2008-01-25 2015-04-23 Chimerix, Inc. Methods of treating viral infections
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
ES2919563T3 (es) * 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US20130072458A1 (en) * 2009-10-30 2013-03-21 Chimerix, Inc. Methods of Treating Viral Associated Diseases
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
US10338069B2 (en) * 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
PT2646470T (pt) 2010-11-30 2017-05-03 Hoffmann La Roche Anticorpos anti-recetor da transferrina de baixa afinidade e a sua utilização na transferência de scfv terapêuticos através da barreira hematoencefálica
CN102172348B (zh) * 2011-02-12 2013-02-20 北京博康宁生物医药科技有限公司 固体的磷酸奥司他韦药物组合物
US8877722B2 (en) * 2011-03-25 2014-11-04 Idera Pharmaceuticals, Inc. Compositions for inhibiting gene expression and uses thereof
JP6208658B2 (ja) 2011-07-05 2017-10-04 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７−抗体結合体および使用方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
WO2013142300A2 (en) 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
KR102434075B1 (ko) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CA3140358A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2906003C (en) 2013-03-13 2021-07-06 Bioasis Technologies Inc. Fragments of p97 and uses thereof
US10287578B2 (en) 2013-06-14 2019-05-14 The University Of Notre Dame DNAzyme-nanoparticle conjugates and methods of use thereof
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
WO2015035337A1 (en) 2013-09-06 2015-03-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3068431A4 (en) * 2013-11-15 2017-08-23 President and Fellows of Harvard College Methods and compositions for the treatment of hcmv
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2935195A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
ES2762672T3 (es) 2014-02-19 2020-05-25 Bioasis Technologies Inc Proteínas de fusión de P97-IDS
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
JP6847664B2 (ja) * 2014-05-01 2021-03-24 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７−ポリヌクレオチド複合体
EP3149161B1 (en) 2014-05-27 2021-07-28 Academia Sinica Fucosidase from bacteroides and methods using the same
AU2015267047A1 (en) 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
EP4116329A1 (en) 2014-05-27 2023-01-11 Academia Sinica Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
CA2984252A1 (en) * 2015-04-29 2016-11-03 Foresight Biotherapeutics, Inc. Therapeutic combinations of antiviral and anti-inflammatory therapies
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
EP3556399A1 (en) * 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
EA202092718A1 (ru) * 2018-05-15 2021-04-29 ФЛЭГШИП ПАЙОНИРИНГ ИННОВЕЙШНЗ VI, ЭлЭлСи Композиции для контроля патогенов и пути их применения
CN111068069B (zh) * 2018-10-18 2022-05-20 中国医学科学院药物研究所 一种免疫靶向功能性脂质体及其制备方法与用途
EP3715374A1 (en) * 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
CA3106735A1 (en) * 2019-05-21 2020-11-26 Universite Laval Crimean-congo hemorrhagic fever virus immunogenic compositions
EP4118085A2 (en) 2020-03-12 2023-01-18 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
EP4221757A1 (en) 2020-09-29 2023-08-09 CRM Therapeutics B.V. Target mediated endocytotic drug delivery
NL2026569B1 (en) * 2020-09-29 2022-05-30 Crm Therapeutics B V Target mediated endocytotic drug delivery
NL2027601B1 (en) * 2021-02-19 2022-09-19 Crm Therapeutics B V Target mediated endocytotic drug delivery
WO2023049762A1 (en) * 2021-09-21 2023-03-30 Washington University Compositions and methods to modulate transfer across the blood-brain barrier
WO2023183628A2 (en) * 2022-03-25 2023-09-28 Judo Bio Inc. Targeted delivery
CN115252760B (zh) * 2022-03-30 2024-05-31 厦门大学 一种广谱抗冠状病毒的制剂及其制备方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3444885B2 (ja) 1992-08-21 2003-09-08 フリーイェ・ユニヴェルシテイト・ブリュッセル Ｌ鎖欠落免疫グロブリン
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
FR2766193B1 (fr) * 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
DK0978285T3 (da) 1998-08-07 2006-03-27 Curis Inc Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
MXPA01006201A (es) * 1998-12-18 2003-06-06 Hadasit Med Res Service Metodo para administrar un compuesto a celulas resistentes a multiples medicamentos.
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
EP1144616B2 (en) 1999-01-19 2009-01-14 Unilever Plc Method for producing antibody fragments
AU3223900A (en) * 1999-02-08 2000-08-25 University Of Maryland At Baltimore Nucleic acid uptake and release vehicle
OA11862A (en) 1999-04-22 2006-03-02 Unilever Nv Inhibition of viral infection using monovalent antigen-binding proteins.
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ES2275563T3 (es) 1999-11-29 2007-06-16 Unilever N.V. Inmovilizacion de proteinas mediante el uso de un segmento polipeptidico.
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
DK1360207T3 (da) 2000-12-13 2011-09-05 Bac Ip B V Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler
NZ526703A (en) 2001-01-22 2004-12-24 Merck & Co Inc Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
EP1383782A1 (en) 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
GB2397062B (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
MXPA05004955A (es) 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
AU2003300544A1 (en) 2003-01-09 2004-08-10 F. Hoffmann-La Roche Ag -modified nucleoside derivatives for treating flaviviridae infections
AU2004204262B2 (en) 2003-01-10 2010-11-04 Ablynx N.V. Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
WO2004069870A2 (en) * 2003-02-10 2004-08-19 To-Bbb Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
CA2523658A1 (en) 2003-04-25 2005-03-03 Intradigm Corporation Rnai agents for anti-sars coronavirus therapy
US7693315B2 (en) * 2003-06-25 2010-04-06 Siemens Medical Solutions Usa, Inc. Systems and methods for providing automated regional myocardial assessment for cardiac imaging
JP2007505606A (ja) 2003-09-16 2007-03-15 サーナ・セラピューティクス・インコーポレイテッド 低分子干渉核酸（ｓｉＮＡ）を使用したＣ型肝炎ウィルス（ＨＣＶ）発現のＲＮＡ干渉媒介性抑制
DE10355559A1 (de) * 2003-11-21 2005-06-23 Orthogen Ag Transskin
WO2005056021A1 (en) 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
AU2005213485A1 (en) 2004-02-05 2005-08-25 Intradigm Corporation Methods and compositions for combination RNAi therapeutics
EP1574572B1 (en) 2004-03-09 2007-05-23 Prosensa B.V. Compounds for hydrolysing ribonucleic acids (RNAs)
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
WO2006031901A2 (en) 2004-09-10 2006-03-23 Somagenics, Inc. SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
EP1647595A1 (en) 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
EP1802643A1 (en) 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
US7592322B2 (en) 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US8691781B2 (en) 2004-11-05 2014-04-08 Sirnaomics, Inc. Compositions for treating respiratory viral infections and their use
WO2006060774A2 (en) 2004-12-02 2006-06-08 Board Of Regents, The University Of Texas System Agents that inhibit flavivirus replication and uses thereof
US20090010907A1 (en) 2004-12-14 2009-01-08 National Institute Of Immunology Dnazymes for Inhibition of Japanese Encephalitis Virus Replication
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
EP2487243A3 (en) 2005-01-07 2013-08-28 Alnylam Pharmaceuticals Inc. RNAI modulation of RSV and therapeutic uses thereof
WO2006096018A1 (en) 2005-03-09 2006-09-14 Mogam Biotechnology Research Institute Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
CA2603842A1 (en) 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US20090221624A1 (en) 2005-05-06 2009-09-03 Olivo Paul D 4-aminoquinoline compounds for treating virus-related conditions
KR20080016597A (ko) 2005-05-13 2008-02-21 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법
KR100733186B1 (ko) 2005-05-31 2007-06-27 재단법인 목암생명공학연구소 Ｈｃｖ 유전자에 특이적인 작은 간섭 ｒｎａ 및 그를유효성분으로 포함하는 ｃ형 간염 치료제
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8067380B2 (en) * 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system

Also Published As

Publication number Publication date
EP2125024A2 (en) 2009-12-02
TWI434699B (zh) 2014-04-21
US20150290234A1 (en) 2015-10-15
WO2008118013A3 (en) 2009-02-19
TWI537005B (zh) 2016-06-11
EP2308514A2 (en) 2011-04-13
EP2308514B1 (en) 2013-06-05
US20100129437A1 (en) 2010-05-27
WO2008118013A2 (en) 2008-10-02
EP2308514A3 (en) 2011-04-20
SI2308514T1 (sl) 2013-09-30
ES2426684T3 (es) 2013-10-24
PT2308514E (pt) 2013-09-06
TW200900081A (en) 2009-01-01
PL2308514T3 (pl) 2013-11-29
DK2308514T3 (da) 2013-09-02
HRP20130547T1 (hr) 2013-08-31
TW201417832A (zh) 2014-05-16
EP2125024B1 (en) 2013-02-13
US20200390794A1 (en) 2020-12-17
US20130216612A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
CY1114116T1 (el) Συζευγματα για στοχευμενη απελευθερωση φαρμακων κατα μηκος του αιματοεγκεφαλικου φραγμου
TR201908314T4 (tr) Glutatyon bazlı ilaç dağıtım sistemi.
ES2856844T3 (es) Inmunoterapia antitumoral combinada
ES2556128T3 (es) ARN interfiriente pequeño internamente segmentado
US9428538B2 (en) Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
WO2009045536A3 (en) Receptor targeted oligonucleotides
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
MX2007012817A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores.
WO2008054826A3 (en) Pathotropic targeted gene delivery system for cancer and other disorders
HK1123728A1 (en) Immuno-rna-constructs
EA201200101A1 (ru) Способ прогнозирования эффективности лекарственных соединений для пациента
ES2531075T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
JP2011254840A (ja) ＭＬＬ−ＡＦ４のＲＮＡｉ調節およびその使用方法
DK2037899T3 (da) Nanopartikler til nukleinsyreafgivelse
EP2949344A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
Villalobos et al. Stability and immunogenicity properties of the gene-silencing polypurine reverse Hoogsteen hairpins
Scaggiante et al. Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors
MX2019005671A (es) Sustancias para direccionar diversos organos o tejidos seleccionados.
WO2008109432A3 (en) Therapeutic targeting of interleukins using sirna in neutral liposomes
EA202091203A1 (ru) Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b
IN2012DN02345A (el)
JP2022550604A (ja) ヌクレオシドアナログを有するオリゴヌクレオチド